CN113271971A - 用于肝病的治疗的组合物和方法 - Google Patents

用于肝病的治疗的组合物和方法 Download PDF

Info

Publication number
CN113271971A
CN113271971A CN201980083971.8A CN201980083971A CN113271971A CN 113271971 A CN113271971 A CN 113271971A CN 201980083971 A CN201980083971 A CN 201980083971A CN 113271971 A CN113271971 A CN 113271971A
Authority
CN
China
Prior art keywords
wisp1
antibody
agent
cell
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980083971.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·Y·崔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Priority to CN202411435476.8A priority Critical patent/CN120305401A/zh
Publication of CN113271971A publication Critical patent/CN113271971A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
CN201980083971.8A 2018-10-19 2019-10-18 用于肝病的治疗的组合物和方法 Pending CN113271971A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411435476.8A CN120305401A (zh) 2018-10-19 2019-10-18 用于肝病的治疗的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862747903P 2018-10-19 2018-10-19
US62/747,903 2018-10-19
PCT/US2019/056910 WO2020081920A1 (en) 2018-10-19 2019-10-18 Compositions and methods for treatment of liver disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411435476.8A Division CN120305401A (zh) 2018-10-19 2019-10-18 用于肝病的治疗的组合物和方法

Publications (1)

Publication Number Publication Date
CN113271971A true CN113271971A (zh) 2021-08-17

Family

ID=70284106

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980083971.8A Pending CN113271971A (zh) 2018-10-19 2019-10-18 用于肝病的治疗的组合物和方法
CN202411435476.8A Pending CN120305401A (zh) 2018-10-19 2019-10-18 用于肝病的治疗的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411435476.8A Pending CN120305401A (zh) 2018-10-19 2019-10-18 用于肝病的治疗的组合物和方法

Country Status (9)

Country Link
US (2) US20210388073A1 (https=)
EP (1) EP3866852A4 (https=)
JP (2) JP2022512735A (https=)
KR (1) KR20210081366A (https=)
CN (2) CN113271971A (https=)
AU (1) AU2019361120A1 (https=)
CA (1) CA3117098A1 (https=)
IL (1) IL282251A (https=)
WO (1) WO2020081920A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117487010A (zh) * 2022-08-02 2024-02-02 东莞市朋志生物科技有限公司 抗四碘甲状腺素抗体或其功能性片段、检测四碘甲状腺素的试剂和试剂盒
CN119331100A (zh) * 2024-10-16 2025-01-21 天津大学 特异性结合25-羟基维生素d的单克隆抗体及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020348295A1 (en) 2019-09-16 2022-04-07 Insmed Incorporated Anti-stem cell factor antibodies and methods of use thereof
EP4051689A4 (en) * 2019-11-01 2023-11-29 Figene, LLC FIBROBLAST THERAPY TO TREAT SCLEROSING CHOLANGITIS
IL322733A (en) * 2023-03-03 2025-10-01 Karydo Therapeutix Inc Antibody or antigen-binding fragment thereof
CN117045680B (zh) * 2023-10-12 2023-12-08 北京国卫生物科技有限公司 促进肝脏再生的干细胞制剂及其制备方法
WO2025179048A2 (en) * 2024-02-20 2025-08-28 Ecogenome Llc Antibodies that bind dach1 and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160165861A1 (en) * 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US20170304442A1 (en) * 2014-04-15 2017-10-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind wisp1
WO2017201422A1 (en) * 2016-05-20 2017-11-23 The General Hospital Corporation Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1027437T3 (da) * 1997-10-29 2008-11-24 Genentech Inc Anvendelse af det WNT-1 inducerede udskilte polypeptid WISP-1
EP1177796B1 (en) * 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
EP1424391A4 (en) * 2001-08-08 2004-09-08 Ajinomoto Kk GROUP OF GENES PARTICIPATING IN THE ACTIVATION OF LIVER ASTROCYTES
CA3102008A1 (en) * 2010-06-02 2011-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170304442A1 (en) * 2014-04-15 2017-10-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind wisp1
US20160165861A1 (en) * 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
WO2017201422A1 (en) * 2016-05-20 2017-11-23 The General Hospital Corporation Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI X.F.等: "Blockade of CCN4 attenuates CCI4–induced liver fibrosis", 《ARCH MED SCI》, vol. 11, no. 3, pages 647 - 653 *
池肇春主编: "《实用临床肝病学》", 30 June 2015, 北京：人民军医出版社, pages: 173 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117487010A (zh) * 2022-08-02 2024-02-02 东莞市朋志生物科技有限公司 抗四碘甲状腺素抗体或其功能性片段、检测四碘甲状腺素的试剂和试剂盒
CN119331100A (zh) * 2024-10-16 2025-01-21 天津大学 特异性结合25-羟基维生素d的单克隆抗体及其应用

Also Published As

Publication number Publication date
KR20210081366A (ko) 2021-07-01
JP2022512735A (ja) 2022-02-07
EP3866852A1 (en) 2021-08-25
US20210388073A1 (en) 2021-12-16
WO2020081920A1 (en) 2020-04-23
CN120305401A (zh) 2025-07-15
AU2019361120A1 (en) 2021-05-13
IL282251A (en) 2021-05-31
CA3117098A1 (en) 2020-04-23
US20250223344A1 (en) 2025-07-10
JP2025011102A (ja) 2025-01-23
EP3866852A4 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
US20250223344A1 (en) Compositions and Methods for Treatment of Liver Disease
JP6633029B2 (ja) 血管新生障害の処置
CA3104868A1 (en) Tissue-specific wnt signal enhancing molecules and uses thereof
EP3315515A1 (en) Fusion protein containing bdnf
TW201522379A (zh) Ｃｈｒｄｌ－１抗原結合蛋白及治療方法
US20260116986A1 (en) Epo receptor agonists and antagonists
JP7470987B2 (ja) 調節ｔ細胞表面抗原のエピトープおよびこれに特異的に結合する抗体
WO2005018671A1 (ja) 癌転移阻害剤
TWI654996B (zh) 微核糖核酸let-7及轉形生長因子β第三類受體調控軸作為心臟損傷標的之用途
KR20240040068A (ko) 메조텔린을 특이적으로 표적화하는 조작된 면역 세포 및 이의 용도
CA3220226A1 (en) Chimeric antigen receptor specifically binding to cd300c antigen or receptor thereof
JP2020510681A (ja) 抗レナラーゼ抗体および抗ｐｄ−１抗体を用いる、がんを処置するための組成物および方法
CA2805270C (en) Treatment of inflammatory disorders
CN120322676A (zh) 可作为治疗慢性肾功能不全和肾纤维化的靶分子adamts12
EP3353196B1 (en) Polypeptides capable of inhibiting the binding between leptin and neuropilin-1
US10398786B2 (en) Therapeutic gene cocktail for heart regeneration
US20260035468A1 (en) New anti-itgb8 antibodies and its uses thereof
KR20240124222A (ko) 조절 t 세포에 특이적으로 존재하는 dkk1 단백질 및 그 용도
JP2025508690A (ja) 癌免疫療法のためのａｒｔ１の標的化
HK40023089A (en) Method for identifying nucleic acids regulating metastasation
HK1193429A (en) Treatment of angiogenesis disorders
HK1193429B (en) Treatment of angiogenesis disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210817